Cargando…

Therapeutic effects of physostigmine during systemic inflammation

INTRODUCTION: Usually, physostigmine is used as antidote for anticholinergic poisons in order to improve hemodynamics and cardiac output. In addition, it causes beneficial effects during sepsis when added timely. Here, we studied whether physostigmine improves hemodynamics when treatment during syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Effenberger-Neidnicht, Katharina, Jägers, Johannes, Verhaegh, Rabea, Kirsch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292228/
https://www.ncbi.nlm.nih.gov/pubmed/30573986
http://dx.doi.org/10.2147/JIR.S187201
_version_ 1783380372982071296
author Effenberger-Neidnicht, Katharina
Jägers, Johannes
Verhaegh, Rabea
Kirsch, Michael
author_facet Effenberger-Neidnicht, Katharina
Jägers, Johannes
Verhaegh, Rabea
Kirsch, Michael
author_sort Effenberger-Neidnicht, Katharina
collection PubMed
description INTRODUCTION: Usually, physostigmine is used as antidote for anticholinergic poisons in order to improve hemodynamics and cardiac output. In addition, it causes beneficial effects during sepsis when added timely. Here, we studied whether physostigmine improves hemodynamics when treatment during systemic inflammation was delayed. METHODS: Two series of randomized studies with overall 44 rats were conducted. Systemic inflammation was induced by lipopolysaccharide (LPS) infusion (0.5 mg LPS/kg×h). Physostigmine (PHY) was intravenously applied after an LPS infusion period of 90 minutes (50 µg PHY/kg within 10 minutes) with (series 1) and without (series 2) additional volume loading. Hemodynamic parameters, blood gases, and parameters for tissue damage were periodically determined for up to 180 minutes. RESULTS: Even though volume was additionally administered (series 1), LPS caused a reduction of peripheral blood flow. Treatment with PHY improved hemodynamics in macrocirculation (mean arterial blood pressure) and microcirculation (peripheral blood flow). PHY neither affected alterations in blood gases, electrolyte homeostasis, and glucose metabolism nor prevented intestinal damage induced by LPS. In series 2, without any additional volume loading, PHY likewise resulted in an improvement of the LPS-induced alterations in macro- and microcirculation, but finally worsened the LPS-mediated effects on plasma parameters for tissue damage such as creatine kinase, probably due to the lack of volume and a further damage to the heart. CONCLUSION: The present results demonstrated that hemodynamic responses to PHY may not only be visible in patients with anticholinergic drug overdose but also be visible in septic patients, provided that fluid intake of these patients is adequate.
format Online
Article
Text
id pubmed-6292228
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62922282018-12-20 Therapeutic effects of physostigmine during systemic inflammation Effenberger-Neidnicht, Katharina Jägers, Johannes Verhaegh, Rabea Kirsch, Michael J Inflamm Res Original Research INTRODUCTION: Usually, physostigmine is used as antidote for anticholinergic poisons in order to improve hemodynamics and cardiac output. In addition, it causes beneficial effects during sepsis when added timely. Here, we studied whether physostigmine improves hemodynamics when treatment during systemic inflammation was delayed. METHODS: Two series of randomized studies with overall 44 rats were conducted. Systemic inflammation was induced by lipopolysaccharide (LPS) infusion (0.5 mg LPS/kg×h). Physostigmine (PHY) was intravenously applied after an LPS infusion period of 90 minutes (50 µg PHY/kg within 10 minutes) with (series 1) and without (series 2) additional volume loading. Hemodynamic parameters, blood gases, and parameters for tissue damage were periodically determined for up to 180 minutes. RESULTS: Even though volume was additionally administered (series 1), LPS caused a reduction of peripheral blood flow. Treatment with PHY improved hemodynamics in macrocirculation (mean arterial blood pressure) and microcirculation (peripheral blood flow). PHY neither affected alterations in blood gases, electrolyte homeostasis, and glucose metabolism nor prevented intestinal damage induced by LPS. In series 2, without any additional volume loading, PHY likewise resulted in an improvement of the LPS-induced alterations in macro- and microcirculation, but finally worsened the LPS-mediated effects on plasma parameters for tissue damage such as creatine kinase, probably due to the lack of volume and a further damage to the heart. CONCLUSION: The present results demonstrated that hemodynamic responses to PHY may not only be visible in patients with anticholinergic drug overdose but also be visible in septic patients, provided that fluid intake of these patients is adequate. Dove Medical Press 2018-12-07 /pmc/articles/PMC6292228/ /pubmed/30573986 http://dx.doi.org/10.2147/JIR.S187201 Text en © 2018 Effenberger-Neidnicht et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Effenberger-Neidnicht, Katharina
Jägers, Johannes
Verhaegh, Rabea
Kirsch, Michael
Therapeutic effects of physostigmine during systemic inflammation
title Therapeutic effects of physostigmine during systemic inflammation
title_full Therapeutic effects of physostigmine during systemic inflammation
title_fullStr Therapeutic effects of physostigmine during systemic inflammation
title_full_unstemmed Therapeutic effects of physostigmine during systemic inflammation
title_short Therapeutic effects of physostigmine during systemic inflammation
title_sort therapeutic effects of physostigmine during systemic inflammation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292228/
https://www.ncbi.nlm.nih.gov/pubmed/30573986
http://dx.doi.org/10.2147/JIR.S187201
work_keys_str_mv AT effenbergerneidnichtkatharina therapeuticeffectsofphysostigmineduringsystemicinflammation
AT jagersjohannes therapeuticeffectsofphysostigmineduringsystemicinflammation
AT verhaeghrabea therapeuticeffectsofphysostigmineduringsystemicinflammation
AT kirschmichael therapeuticeffectsofphysostigmineduringsystemicinflammation